- Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study
-
Sugimoto T, Yoshimura T, Uzawa T
- KMID: 2514815
- Osteoporos Sarcopenia.
- 2021 Mar;7(1):11-16.
- doi: 10.1016/j.afos.2020.12.001
Objectives: To assess differences in efficacy of a 28.2-μg teriparatide formulation for twice-weekly use (2/W-TPTD) by patient characteristics. Methods: A post hoc analysis was performed using data from a multicenter, randomized,... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between elcatonin use and cancer risk in Japan: A followup study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis
-
Okamoto H, Shibazaki N, Yoshimura T, Uzawa T, Sugimoto T
- KMID: 2503796
- Osteoporos Sarcopenia.
- 2020 Mar;6(1):15-19.
- doi: 10.1016/j.afos.2020.02.001
Objectives: On July 20, 2012, the European Medicines Agency (EMA) provided a recommendation that limits the long-term use of calcitonin. Based on this recommendation, we investigate the presence or absence... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk
-
Ifuku E, Yoshimura , Uzawa T, Hokonohara T
- KMID: 2463605
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):44-50.
- doi: 10.1016/j.afos.2019.06.002
OBJECTIVES: To reassess the safety and efficacy of once-weekly teriparatide 56.5 mg in osteoporosis patients with a high fracture risk. METHODS: This postmarketing observational study was conducted at 72 weeks according... -
- CITED
-
- Close
- SHARE
-
- Close
